leisure time -WSS

leisure time

author：focus 2025-08-19 15:01:37 - browse：723

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Merck drug for rare lung condition set for approval in U.S.

entertainment

hotspot

WSS

Winning ticket for $1 billion Powerball jackpot sold in California

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Readout Newsletter: Merck, Vertex, and Viking updates

EF3 tornado rips through North Carolina amid extreme weather nationwide

Covid vaccine financial winners and losers, from Pfizer to Novavax

hotspot

leisure time

Wikipedia

What does generative AI mean for health care? We asked experts

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Duchenne breakthrough therapy leaves behind pioneering families

Ending racial health disparities hinges on penalties, political will

Peter Hotez and the public health issue of online harassment

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Apple is now the first public company to be valued at $3 trillion

Tocagen's brain cancer gene therapy trial continues. Investors worry

Medicare details structure of new drug price negotiation program

Readout LOUD podcast: mifepristone case, GLP

knowledge

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Winning ticket for $1 billion Powerball jackpot sold in California

Divers poised to search for children washed away in Pennsylvania flash flood

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Supreme Court mifepristone arguments center on docs' right to sue

Stanford president's case begs question: Who takes blame?

entertainment

entertainment

hotspot

focus